$39.7 Million is the total value of Foresite Capital Opportunity Management V, LLC's 9 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 66.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| QSI | Sell | Quantum-Si Incorporated | $1,470,000 | -80.3% | 633,626 | -60.4% | 3.70% | -64.6% |
| CGEM | Exit | Cullinan Oncology, Inc. | $0 | – | -330,836 | -100.0% | -4.85% | – |
| Exit | Cue Health Inc. | $0 | – | -641,483 | -100.0% | -5.79% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Pardes Biosciences Inc | 4 | Q3 2022 | 57.4% |
| Theseus Pharmaceuticals, Inc. | 4 | Q3 2022 | 16.7% |
| Gemini Therapeutics, Inc. | 4 | Q3 2022 | 12.0% |
| Quantum-Si Incorporated | 4 | Q3 2022 | 10.5% |
| Kinnate Biopharma Inc. | 4 | Q3 2022 | 10.5% |
| Compass Therapeutics, Inc. | 4 | Q3 2022 | 10.6% |
| Adicet Bio, Inc. | 4 | Q3 2022 | 7.3% |
| Enanta Pharmaceuticals, Inc. | 3 | Q3 2022 | 3.5% |
| Cue Health Inc. | 2 | Q1 2022 | 13.7% |
| Cullinan Oncology, Inc. | 2 | Q1 2022 | 4.8% |
View Foresite Capital Opportunity Management V, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-05 |
| 4 | 2023-08-31 |
| 4 | 2023-07-19 |
| 4 | 2023-05-10 |
| 4 | 2023-04-06 |
| 4 | 2023-02-22 |
| 4 | 2023-01-03 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
| 3 | 2022-06-13 |
View Foresite Capital Opportunity Management V, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.